Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
15 studies found for:    Ampligen
Show Display Options
Rank Status Study
1 Active, not recruiting Ampligen in Chronic Fatigue Syndrome
Condition: Chronic Fatigue Syndrome
Intervention: Drug: Poly I: Poly C12U (Rintatolimod)
2 Terminated Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
Conditions: HIV Seropositivity;   HIV Infection
Intervention: Drug: poly I-poly C12U
3 Completed The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
Conditions: HIV Seropositivity;   HIV Infection
Intervention: Drug: poly I-poly C12U
4 Completed A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC
Condition: HIV Infections
Intervention: Drug: Ampligen
5 Completed A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects
Condition: HIV Infections
Intervention: Drug: Ampligen
6 Completed A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen
Condition: HIV Infections
Interventions: Drug: Ampligen;   Drug: Zidovudine
7 Terminated Safety Study of FluMist With and Without Ampligen
Condition: Influenza, Human
Interventions: Drug: FluMist + Poly I:Poly C12U 50 ug;   Drug: FluMist + Poly I:Poly C12U 200 ug;   Drug: FluMist + Poly I:Poly C12U 500 ug;   Drug: FluMist + Poly I:Poly C12U 1250 ug;   Drug: FluMist + Placebo
8 Active, not recruiting Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: sargramostim;   Drug: rintatolimod
9 Completed A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection
Condition: HIV Infections
Intervention: Drug: Ampligen
10 Completed The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Ampligen
11 Active, not recruiting A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Biological: OC-L/Montanide ISA 51 VG;   Biological: Ampligen;   Biological: Prevnar
12 Not yet recruiting A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Biological: αDC1 vaccine;   Drug: CKM
13 Recruiting αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
Conditions: Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface;   Malignant Peritoneal Mesothelioma;   Peritoneal Carcinomatosis
Interventions: Biological: DC vaccine;   Drug: Celecoxib;   Drug: Interferon Alfa-2b;   Biological: rintatolimod
14 Recruiting Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Conditions: Colorectal Cancer;   Colorectal Carcinoma;   Colorectal Tumors;   Neoplasms, Colorectal
Intervention: Drug: Chemokine modulatory regimen
15 Recruiting Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Conditions: Cancer of Ovary;   Cancer of the Ovary;   Neoplasms, Ovarian;   Ovarian Cancer;   Ovary Cancer;   Ovary Neoplasms
Interventions: Biological: Cisplatin + celecoxib + DC vaccine;   Biological: Cisplatin + CKM + Celecoxib + DC Vaccine

Study has passed its completion date and status has not been verified in more than two years.